The slice method results were within a 3-fold range of the in vivo results for all but one compound, suggesting that this method could be used in combination with total drug levels to estimate unbound interstitial fluid concentrations within reasonable limits. Although successful in 10 of 15 cases, the brain homogenate binding method failed to estimate the V u,brain of drugs that reside predominantly in the interstitial space or compounds that are accumulated intracellularly. Use of the simple methods described in this paper will 1) allow quantification of active transport at the BBB in vivo, 2) facilitate the establishment of a relationship between in vitro potency and in vivo activity for compounds acting on CNS targets, and 3) provide information on intracellular concentrations of unbound drug.
Introduction
Determination of drug levels in the brain tissue of experimental animals is routinely undertaken in drug discovery programs for various purposes, including studies on blood-brain barrier (BBB) transport and equilibration. Drug levels are also studied in conjunction with pharmacodynamic experiments in order to link in vivo effects with in vitro potency, or to elucidate the mechanism and site of action. The practical approach to routinely investigating large numbers of new compounds has been to measure the amount of drug in brain (A brain ), which is given in amount per gram brain and therefore commonly referred to as the total brain concentration.
Since assessment of A brain has historically been the most common method of measuring CNS exposure in drug discovery, medicinal chemistry programs have favored compounds and classes displaying high total CNS-to-plasma concentration ratios. This type of data, expressed as "logBB", has resulted in the establishment of general criteria for physicochemical properties of compounds with potentially high or low CNS exposure (Kelder et al., 1999) .
Although this method has the advantage of experimental simplicity, the use of total tissue levels (A brain ) is also associated with limitations. It is generally accepted that it is the unbound drug that exerts the effect on the receptor. Large amounts of drug in the brain do not necessarily mean high concentrations available to the receptor, since the drug may bind to or dissolve in tissue components. Measurements of A brain alone can thus be very misleading.
Similarly, a high brain-to-plasma ratio based on measurements of A brain may be reflective of extensive binding to brain tissue rather than of unrestrained transport across the BBB.
According to the free drug hypothesis, the unbound drug concentration in tissue is equal to the unbound drug concentration in plasma at equilibrium. This may not be the case for brain DMD #15222 6 tissue since there are active efflux and influx processes at the BBB. Cerebrospinal fluid (CSF) drug concentrations are potentially more closely related to the concentrations of unbound drug in brain interstitial fluid (C u,brainISF ), because of the separation from blood by the blood-CSF barrier. Also the ependymal lining of the ventricles allows diffusional and convectional exchange with the brain interstitium (Abbott, 2004; Liu et al., 2006) . However, the CSF represents a different compartment and the turnover of CSF is different from that of brain ISF (Abbott, 2004) . Investigations have demonstrated that drug concentrations in the CSF are not necessarily equal to those in brain ISF (de Lange and Danhof, 2002; Shen et al., 2004) . The only method of directly measuring C u,brainISF is microdialysis. Unfortunately, the utility of this method in drug discovery programs is limited by the time requirements and by specific technical difficulties with lipophilic drugs. Wang and Welty (1995) introduced the unbound volume of distribution in the brain (V u,brain ) to relate C u,brainISF to A brain , where V blood ×C blood is the amount of drug present in the blood vessels of the brain: Thus, V u,brain describes the distribution of drug inside the brain regardless of brain-to-plasma distribution. A low value for V u,brain , close to the volume of the interstitial space, would thus describe predominantly extracellular distribution, while a high value would indicate that the drug enters brain cells and binds to tissue components (Gupta et al., 2006) .
If the value of V u,brain can be reliably obtained for a compound, C u,brainISF can be calculated from available total drug levels, thus circumventing the need for microdialysis. Methods other than microdialysis that have been used for estimating V u,brain include the brain slice uptake DMD #15222
Materials and methods

Compound selection
The literature was searched for microdialysis reports containing both unbound and total brain drug concentrations, i.e. the data needed to calculate V u,brain . Studies that were performed using probe calibration in vivo by retrodialysis were favored. Nearly every compound that fulfilled the criteria was included in the study. The set of fourteen compounds listed in Table   1 is pharmacologically diverse, including opioids and their metabolites (morphine, codeine, oxycodone, morphine-3-glucoronide, morphine-6-glucuronide), anti-infectives (alovudine, norfloxacin), antihistamines (R-and S-cetirizine), dopamine agonists (R-and Sapomorphine), an anxiolytic (diazepam), an anticonvulsant (gabapentin) and an anesthetic agent (thiopental). The set is also chemically diverse in terms of ionization state at pH 7.4 and lipophilicity (Table 1) . However, it was recognized that most of the included drugs were less lipophilic than the majority of compounds in contemporary drug discovery programs. To balance this, additional microdialysis experiments were performed with a lipophilic base (CP-122721) and included in the study.
Chemicals
Alovudine (3'-fluorothymidine), R,S-apomorphine, codeine, diazepam, 14 C-inulin, Kaninfarm (Lidköping, Sweden). All animals were group housed at 18-22°C under a 12 h light-dark cycle with free access to food and water for at least five days before the experiment. The study was approved by the Animal Ethics Committee of Göteborg (346-2002 Göteborg (346- , 412-2005 .
Intracerebral microdialysis of CP-122721
Adsorption to the FEP tubing (CMA microdialysis, Solna) and CMA/12 probe necessitated the inclusion of 0.5 % BSA in the perfusion fluid, as described previously (Gupta et al., 2006) . Probe recovery and delivery of CP-122721 were found in vitro to be equal, supporting the use of the in vivo retrodialysis calibration method. In vivo experiments in rats were performed as previously described (Bostrom et al., 2006) . After retrodialysis and washout with blank perfusate, the drug was administered intravenously as a bolus dose plus a fourhour constant rate infusion to obtain steady state. The size of the bolus dose and the infusion rate were adjusted according to the plasma pharmacokinetics. CP-122721 was dissolved in saline. Microdialysate samples were collected at 20-minute intervals from two hours post bolus dose until the termination of the experiment at four hours when brain tissue was sampled. V u,brain was calculated using eq. 1, assuming a blood volume of 3 % of brain weight (Shockley and LaManna, 1988) and a blood/plasma distribution ratio of unity.
Brain slice uptake experiments
The brain slice uptake experiments were performed as described previously (Kakee et al., 1996) , with minor modifications. Drug-naïve animals were sacrificed under isoflurane anesthesia, and the brain was removed and immersed in ice-cold oxygenated pH 7.4 ECF buffer (NaCl, 122; NaHCO 3 , 25; glucose, 10; KCl, 3; CaCl 2 , 1.4; MgSO 4 , 1.2; K 2 HPO 4 , 0.4; and 4-(2-hydroxyethyl)-n-piperazine ethanesulfonic acid, 10 mmol/L). A 6 mm coronal section was cut with a razor and mounted with cyanoacrylate glue onto the tray of a DTKZero1 Microslicer (Dosaka instruments, Japan). Eight 300 µm coronal slices of striatal areas were cut. The slices were preincubated at 37 °C for 5 minutes in 10 ml ECF buffer before the drug, dissolved in ECF buffer, was added. The concentration of drug in the buffer was chosen to match the brain unbound drug concentrations observed in the corresponding in vivo microdialysis experiment. The incubations were continuously supplied with a mixture of 5% carbon dioxide in oxygen, keeping the bubbles at some distance from the slice. At prespecified time points after addition of drug (15, 30, 60, 120 and 240 minutes) , the slice (~40 mg) was removed from the solution, dried on filter paper and weighed. The slices were homogenized in 9 volumes (w/v) of de-ionized water with an ultrasonic probe (Branson Sonifier 250, Banburry, CT, USA). The ECF buffer and the slice homogenates were stored at -20°C until analysis. V u,brain was calculated according to eq. 2 where A slice , C buffer and V i are the amount of drug in the slice, the concentration of drug in ECF buffer, and the adherent water volume, respectively.
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Brain homogenate binding
Drug-naïve animals were sacrificed under isoflurane anesthesia, the brain was removed and three volumes of a 180 mmol/L phosphate buffer (pH 7.4) were added. The brains were homogenized on ice with an ultrasonic probe and stored at -20°C until required, when the brain homogenate was thawed and the drug added. Equilibrium dialysis of 1 mL homogenate and buffer was performed in triplicate for 16 hours at 37 °C in 1 mL plexi-glass cells mounted with a 5 kD cut-off Diachema cellulose membrane (Dianorm GmbH, München, Germany).
An aliquot of homogenate was sampled before and after co-incubation to assess the compound stability. The fraction of unbound drug in diluted brain homogenate, f u,hD , i.e. the buffer-to-homogenate concentration ratio, was used to calculate V u,brain , while also taking into 
The equation describes a relationship where the lowest possible V u,brain is 0.8 mL*g brain -1 if there is no binding and the drug occupies only the brain water space. This is an inherent limitation of the technique for V u,brain predictions of compounds that approach the lowest possible value in vivo, which is the volume of the brain interstitial fluid (0.2 mL*g brain -1 ).
The chemical instability of apomorphine enantiomers necessitated the use of 50 mmol/L ascorbic acid in the buffer for brain homogenization and equilibrium dialysis. Samples containing apomorphine were stored at -70°C until analysis.
V u,brain predictions based on LogD 7.4
A simple V u,brain prediction model was established using linear regression analysis of in vivo Log V u,brain and LogD 7.4 of the studied compounds. The in vivo V u,brain for each compound was predicted from its LogD 7.4 using the regression line of the other compounds, not including itself. Calculated ACDLogD7.4 values (Table 1) were used for all compounds except morphine glucuronides and cetirizine, for which experimentally obtained values from the literature were considered more reliable.
Analytical procedures
The amount of drug in the various sample matrices was quantified with reversed phase liquid chromatography and multiple reaction monitoring mass spectrometry (LC-MS/MS) detection using a Micromass Quattro Ultima instrument (Waters, Manchester, UK) equipped with electrospray run in positive mode for all compounds except thiopental. Gradient elution over 2 minutes with acetonitrile and formic acid 0.2 % with a flow rate of 0.6 mL/min was used.
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Sample preparation was adapted for any compound specific requirements but followed a general procedure: buffer samples (100 µL) from the brain slice and brain homogenate experiments were added to a 96-deepwell plate (Nalgen Nunc International, NY) and diluted with a volume of 0.2 % formic acid containing an appropriate amount of acetonitrile. Fifty µL samples of brain homogenates were protein precipitated with 150 µL cold acetonitrile containing 0.2 % formic acid. After 1 min vortexing and 20 min centrifugation at 4000 rpm (Rotanta/TR, Hettich, Tuttlingen, Germany) at 4°C, the supernatant was transferred to a new plate and appropriately diluted with 0.2 % formic acid. Microdialysis samples containing 0.5 % BSA were protein precipitated in a similar manner. External calibration curves with at least five different concentrations were made from a serial dilution in 50 % acetonitrile and 0.2 % formic acid by standard addition to the blank matrices in a 1:9 volume ratio. Enantioselective analysis of cetirizine was undertaken using a previously reported method (Gupta et al., 2005) .
The coefficient of correlation R 2 for each calibration curve was 0.990 or higher.
Radioactive isotopes were quantified using a Wallac WinSpectral 1414 liquid scintillation counter (Turku, Finland) and an OptiPhase 'HiSafe 3' scintillation cocktail (Fisher Chemicals, Loughborough, England). Brain slices were solubilized with 1 mL Soluene-350 (Perkin Elmer, Boston, MO) and decolorized with 100 µL hydrogen peroxide.
Data presentation and statistical analysis
Values of V u,brain are expressed as means ± standard deviation. with in vivo V u,brain data was assessed according to Altman and Bland (Altman and Bland, 1983; Bland and Altman, 1999) . For each in vitro method, the significance of the mean bias was tested with Student's t-test. The agreement is expressed as the 90 % confidence interval ratio (CIR) around the mean, which was calculated using the t-distribution. The 90 % CIR indicates the likely difference for a future single compound mean across 7 slices or 3 dialysis cells. The 90% confidence interval is the mean difference (bias) divided by the CIR to the mean difference multiplied by the CIR. The in vivo agreement of the LogD 7.4 -based prediction model was also assessed using 90 % CIR.
Definitions and relationships
The basic assumption of this study was that the intra-brain distribution of a drug can be described by a distributional model in which the drug is unbound in the brain ISF.
Distribution occurs by permeation into brain cells and by binding to membranes or proteins located intra-or extracellularly (Fig. 1) . Specifically, we assumed that C u,brainISF measured with a microdialysis probe was representative of the whole brain, i.e. that there would be only limited regional variations in the brain-to-plasma unbound drug concentration ratio. Morphine has been studied in rats and pigs indicating some spatial differences (Matos et al., 1992; Tunblad et al., 2004) whereas carbamazepine showed no differences in the rat (Van Belle et al., 1995) .
The V u,brain value, in mL*g brain -1 with brain ISF as the reference fluid, reflects the distribution of the drug inside the brain, as distinct from the brain-to-plasma concentration ratio. synonymous with the brain-to-plasma concentration ratio and has blood or plasma as reference. The V D term is commonly used with respect to the intravenous injection technique (Patlak et al., 1983) , the in situ brain perfusion method (Dagenais et al., 2000) and positron emission tomography (PET) (Koeppe, 2002) .
Equations were derived from the definition of V u,brain (eq. 1) and the distributional model ( ) is also introduced, as this relates A cell to the intracellular concentration of unbound drug, C u,cell (µmol*mL ICF -1 ):
Replacing eq. 6 into eq. 5 and dividing by C u,brainISF gives:
It can be seen from eq. 7 that, if no drug enters the brain parenchymal cells, C u,cell is zero and V u,brain becomes equal to the volume of ISF, typically a value around 0.2 ml*g brain -1 (Nicholson and Sykova, 1998) . This is, from a physiologic perspective, the smallest V u,brain
This article has not been copyedited and formatted. The final version may differ from this version. (Reinoso et al., 1997) may indicate even distribution in the whole brain tissue. Likewise, a V u,brain larger than 0.8 suggests that the drug has affinity for brain tissue.
It cannot be directly assumed that the concentration of unbound drug in brain ICF is equal to the concentration of unbound drug in brain ISF. Apart from the effects of active transport mechanisms, the lower intracellular pH could cause basic drugs to be trapped intracellularly, as they are not able to permeate the cell membrane in their ionized form. Assuming for acidic and basic drugs that passive diffusion of the un-ionized species dominates permeation of the membrane, the distribution of unbound drug at equilibrium is determined by the drug pKa and the pH in the extra-and intracellular compartments, pH ISF and pH cell , respectively (eq. 8, 9). 
Results
The in vivo V u,brain of the compounds in this study spanned three orders of magnitude, from 0.2 mL*g brain -1 for the morphine glucuronides, indicating exclusive distribution outside brain cells and minimal binding to proteins or membranes, to 210 mL*g brain -1 for CP-122721, revealing extensive tissue binding and distribution to the intracellular space (Table   3 ). Values for V u,brain obtained with the investigated methods are also illustrated in Fig.s 2-3 .
The distribution volume of the extracellular marker 14 C-Inulin after 4 hours' incubation was 0.36 ± 0.037 mL*g brain -1 . As the cell viability from a slice preparation is difficult to assess absolutely or quantitatively, the levels of ATP were monitored during the incubation period.
There was little change in ATP concentration from the time of preparation of the brain slice to the end of the 4-hour incubation (~8 nmol*mg protein -1 ). The V u,brain of 3 H-GABA, used to demonstrate functionality in terms of cellular transport, reached a maximum (17 ± 4.7 mL*g brain -1 ) after 60 minutes and then slowly declined.
The time course of drug uptake in the brain slices was studied by terminating the incubations at various prespecified times (Fig. 2) . The extent of uptake of these compounds clearly varied, but they also differed in the time required to reach equilibrium. Since all the compounds had reached equilibrium at 240 minutes, this time point was used in the calculations. Variability of V u,brain in slices from different rats was not greater than variability in slices from the same rat (data not shown).
Characterization of the brain homogenate binding method included time course studies using diazepam and gabapentin. Because these indicated that 8 hours of incubation was necessary to achieve equilibrium between the dialysis cells, overnight incubation for 16 hours was This article has not been copyedited and formatted. The final version may differ from this version. Agreement between the methods is illustrated in Fig. 3 , in which in vitro V u,brain determined by the slice or homogenate methods was plotted against in vivo V u,brain determined by microdialysis. The brain slice method predicted V u,brain within a 3-fold range for all but 1 of the 15 compounds, while the brain homogenate binding technique predicted V u,brain within a 3-fold range for 10 of the 15 compounds. There was no statistically significant bias for the in vitro methods in relation to the in vivo data ( Table 4 ). The 90 % CIRs expressing the likely (fold) difference compared to the in vivo data were 3.0 and 6.0 for the slice and homogenate methods, respectively (Table 4 ).
There were instances of deviations from agreement between the methods. For example, the homogenate V u,brain for morphine-3-glucuronide (1.3 mL*g brain , respectively, indicating that the total amount in brain was much higher than ISF concentrations of unbound gabapentin. Conversely, the reverse situation was seen with both cetirizine enantiomers: the brain homogenate method indicated considerable binding to brain tissue (V u,brain 12 mL*g brain -1 ) that was indicated to a lesser extent in the slice method (6.5 mL*g brain -1
) compared to in vivo with microdialysis (2.5 mL*g brain gabapentin, which is actively transported into brain cells by the system L α-amino acid transporter (Su et al., 1995) . As this process cannot be captured in the homogenate method, the V u,brain value of close to 1 contrasted with the higher in vivo value of 5.5 and the slice V u,brain value of 4 mL*g brain -1 .
As suggested by the gabapentin result, the V u,brain value for any transporter substrate at the level of brain parenchymal cells will vary according to which of these methods is used.
Multidrug resistance-associated proteins (MRPs) have been located beyond the BBB in microglia, astrocytes, neurons and oligodendrocytes (Dallas et al., 2006) . Whenever V u,brain is influenced by active transport mechanisms in the brain parenchyma, the slice method can be expected to provide more accurate estimates. Furthermore, intracellular accumulation of basic drugs will also occur as the ionized species is trapped by the lower pH of the intracellular fluid. C u,cell could potentially be 2-fold higher than C u,brainISF , depending on the pKa of the drug and assuming a difference of 0.3 pH units between intra-and extracellular compartments (Davson and Segal, 1996) . This phenomenon was observed for the basic model compounds in our study.
Whereas the cells are entirely disrupted in the brain homogenate method, the cellular integrity of incubated brain slices could also be compromised near the cut surfaces, thus affecting discrimination between intra-and extracellular compartments. In fact, the measured slice distribution volume of the extracellular marker 14 C-inulin (0.36 ml*g brain -1
) was higher than
in vivo values (Nicholson and Sykova, 1998) . Slice viability, measured as the ATP levels, was stable; ATP levels were similar to those in previous reports (12-14 nmol*mg protein -1 ) (Lipton and Whittingham, 1984) . Liu and Chen, 2005; Syvanen et al., 2006) . Thus, the interest in estimating V u,brain is associated with the ability to convert A brain to C u,brainISF .
Suggested applications of V u,brain measurements are outlined in Appendix I.
It is doubtful if there will ever be a direct way of measuring C u,cell . The difficulty is in knowing whether the cell-associated amount of drug reflects cellular binding or the uptake and efflux processes that determine C u,cell . In this paper, we have provided a theoretical This article has not been copyedited and formatted. The final version may differ from this version. framework and methodology for making that discrimination; the slice method gives the amount of drug associated with the cells (A cell ) which is, in turn, converted to C u,cell with the homogenate estimate of intracellular binding (V u,cell ). This integrative use of the slice and homogenate methods allowed us to estimate the slice C u,cell /C u,brainISF ratio (K p,uu,cell ) for the 15 study compounds. In effect, the slice and homogenate methods may be used in parallel to provide insight into whether active transport systems are operating beyond the BBB. This was clearly observed for gabapentin in comparison with the other drugs. The framework of C u,cell estimations could also be adapted to tissues other than brain and used in a variety of research areas.
In conclusion, there is a recognized need in drug discovery programs for methods of estimating unbound drug concentrations in the brain in an efficient, reliable manner. Table 3 . Tables   Table 1. Physicochemical description of drugs included in the study. Values of LogD 7.4 (ACDLogD pH7.4) and pKa (ACDpKa) were calculated using ACDlabs databases version 9.03 (Advanced Chemistry Development Inc., Toronto, Canada). (Avdeef et al., 1996) This article has not been copyedited and formatted. The final version may differ from this version. 
